Holen Sie sich die Stockscreener-App
25.61
1.99%
0.50
Vorhandelsmarkt:
25.75
0.14
+0.55%
Schlusskurs vom Vortag:
$25.11
Offen:
$25.2
24-Stunden-Volumen:
477.95K
Relative Volume:
0.73
Marktkapitalisierung:
$1.88B
Einnahmen:
$105.97M
Nettoeinkommen (Verlust:
$-81.13M
KGV:
-23.73
EPS:
-1.0791
Netto-Cashflow:
$-35.43M
1W Leistung:
+7.02%
1M Leistung:
-10.23%
6M Leistung:
+6.62%
1J Leistung:
+123.08%
1-Tages-Spanne:
$24.94
$25.68
1-Wochen-Bereich:
$23.87
$25.68
52-Wochen-Spanne:
$11.02
$29.75
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
25.61 | 1.85B | 105.97M | -81.13M | -35.43M | -1.0791 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-10-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
ZYME SEC FilingsZymeworks 10-K, 10-Q, 8-K Forms - Stock Titan
Zymeworks Inc. (ZYME) - Minichart
Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality (ZYME) - Seeking Alpha
ZYME Technical Analysis | Trend, Signals & Chart Patterns | ZYMEWORKS INC (NASDAQ:ZYME) - ChartMill
Zymeworks authorizes fresh $125M share buyback - MSN
Zymeworks Inc stock (US98985W1080): buyback plan and insider equity awards draw fresh attention - AD HOC NEWS
Zymeworks grants RSUs and options to EVP | ZYME Insider Trading - Stock Titan
Zymeworks (ZYME) EVP files Form 3 reporting no share ownership - Stock Titan
Rubric Capital, David Rosen disclose 9.49% stake in Zymeworks (ZYME) - Stock Titan
Vanguard Group Inc. Increases Position in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock - The Manila Times
Zymeworks Authorizes 2026 Share Repurchase Program, Affirms Liquidity - TipRanks
Zymeworks authorizes $125 million share buyback program - Investing.com UK
Zymeworks authorizes $125 million share buyback program By Investing.com - Investing.com South Africa
Tranche Update on Zymeworks Inc.'s Equity Buyback Plan announced on November 18, 2025. - marketscreener.com
Zymeworks (NASDAQ: ZYME) launches $125M stock buyback and outlines runway - Stock Titan
Zymeworks Inc.'s Equity Buyback announced on November 16, 2025, has expired with 4,197,553 shares, representing 5.62% for $102.3 million. - marketscreener.com
Zymeworks to present at three major investor conferences in May and June 2026 - Pluang
Zymeworks Announces Participation in Upcoming Investor Conferences - Koreabizwire
About Us | Cabling Installation & MaintenanceZymeworks Announces Participation in Upcoming Investor Conferences - FinancialContent
Zymeworks Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ZYME) 2026-05-12 - Seeking Alpha
Earnings call transcript: Zymeworks reports Q1 2026 revenue drop, outlines strategic advancements - Investing.com India
Earnings call transcript: Zymeworks reports Q1 2026 revenue drop, outlines strategic advancements By Investing.com - Investing.com Australia
Zymeworks Q1 2026 presentation: $250M milestone eyed amid revenue dip - Investing.com
Here's What Analysts Are Forecasting For Zymeworks Inc. (NASDAQ:ZYME) After Its First-Quarter Results - Yahoo Finance
Citizens reiterates Zymeworks stock rating on pipeline progress - Investing.com
How Wider Q1 Losses and FDA Priority Review for Zanidatamab At Zymeworks (ZYME) Has Changed Its Investment Story - simplywall.st
Zymeworks Q1 Earnings Call Highlights - TradingView
Number of shareholders of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Zymeworks (ZYME) Q4 Loss And TTM US$81 Million Deficit Test Bullish Profitability Narrative - Sahm
Zymeworks Q1 2026 presentation: zanidatamab nears FDA decision By Investing.com - Investing.com South Africa
Zymeworks Down Over 9%, on Pace for Largest Percent Decrease Since December 2022 -- Data Talk - Moomoo
Zymeworks (NASDAQ:ZYME) Trading Down 8.9% After Earnings Miss - MarketBeat
Wells Fargo & Company Forecasts Strong Price Appreciation for Zymeworks (NASDAQ:ZYME) Stock - MarketBeat
Zymeworks Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Zymeworks Inc. (NASDAQ:ZYME) Q1 2026 Earnings Call Transcript - Insider Monkey
Zymeworks Inc. (ZYME) reports Q1 loss, misses revenue estimates - MSN
Zymeworks Inc. (ZYME) Stock Analysis: Exploring a 50% Upside Potential Amidst Strong Buy Ratings - DirectorsTalk Interviews
Zymeworks Q1 2026 presentation: zanidatamab nears FDA decision - Investing.com
Earnings call transcript: Zymeworks faces revenue decline in Q1 2026 By Investing.com - Investing.com Canada
Earnings call transcript: Zymeworks faces revenue decline in Q1 2026 - Investing.com
Zymeworks (ZYME) Q1 2026 Earnings Transcript - The Globe and Mail
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Zymeworks Reports Q1 2026 Results and Pipeline Progress - TipRanks
Earnings Flash (ZYME) Zymeworks Inc. Reports Q1 Revenue $2.4M - marketscreener.com
Q1 2026 Zymeworks Inc Earnings Call Transcript - GuruFocus
Aug. 25 FDA decision could trigger $250M milestone for Zymeworks - Stock Titan
Zymeworks (NASDAQ: ZYME) monetizes Ziihera royalties and boosts cash above $400M - Stock Titan
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):